Nanosuspension formulation

1. A nanosuspension comprising (a) a pharmaceutical active ingredient or nutraceutical active ingredient having a solubility of 0.1-1 mg/mL or less than 0.1 mg/mL in water at 20° C. ; (b) at least one alginate selected from the group consisting of (i) sodium alginate having a viscosity of 100 mPa·s or less in a 1% solution in water at 20° C. and (ii) potassium alginate; and (c) water.

2. The nanosuspension of claim 1 wherein the pharmaceutical active ingredient or nutraceutical active ingredient comprises between 0.1 and 10 percent by weight of the nanosuspension.

3. The nanosuspension of claim 2 wherein the pharmaceutical active ingredient or nutraceutical active ingredient comprises between 0.5 and 5 percent by weight of the nanosuspension.

4. The nanosuspension of claim 3 wherein the pharmaceutical active ingredient or nutraceutical active ingredient comprises between 0.5 and 3 percent by weight of the nanosuspension.

5. The nanosuspension of claim 1 wherein the alginate is present in an amount between 0.1 and 20 percent by weight, based upon the weight of the pharmaceutical active ingredient or nutraceutical active ingredient.

6. The nanosuspension of claim 5 wherein the alginate is present in an amount between 0.25 and 5 percent by weight, based upon the weight of the pharmaceutical active ingredient or nutraceutical active ingredient.

7. The nanosuspension of claim 6 wherein the alginate is present in an amount between 0.35 and 2 percent by weight, based upon the weight of the pharmaceutical active ingredient or nutraceutical active ingredient.

8. The nanosuspension of claim 1 wherein the alginate comprises said sodium alginate.

9. The nanosuspension of claim 1 wherein the alginate comprises said potassium alginate.

10. The nanosuspension of claim 9 wherein the potassium alginate has a viscosity of 500 mPa·s or less in a 1% solution in water at 20° C.

11. The nanosuspension of claim 1 wherein the pharmaceutical active ingredient is selected from the group consisting of a nonsteroidal anti-inflammatory drugs, immunosuppressant drugs, atopic dermatitis drugs, calcium channel blockers, angiotensin II antagonists, cholesterol synthesis-inhibiting hypolipidemic agents, cholesterol metabolism- and secretion-promoting hypolipidemic agents, antidiabetic drugs, lipase inhibitors, antifungal agents, hepatoprotective drugs, gastrointestinal drugs, antiplatelet agents, osteoporosis drugs, antiviral drugs, antibiotics, antiasthmatic or antihistamine drugs, hormone drugs and anticancer drugs.

12. The nanosuspension of claim 1 wherein the pharmaceutical active ingredient is selected from the group consisting of acetaminophen, acetylsalicylic acid, ibuprofen, fenbuprofen, fenoprofen, flurbiprofen, indomethacin, naproxen, etodolac, ketoprofen, dexibuprofen, piroxicam, aceclofenac, cyclosporin, tacrolimus, rapamycin, mycophenolate, pimecrolimus, nifedipine, nimodipine, nitrendipine, nilvadipine, felodipine, amlodipine, isradipine, valsartan, eprosartan, irbesartan, candesartan, telmisartan, olmesartan, losartan, atorvastatin, lovastatin, simvastatin, fluvastatin, rosuvastatin, pravastatin, gemfibrozil, fenofibrate, etofibrate, bezafibrate, pioglitazone, rosiglitazone, metformin, orlistat, itraconazole, amphotericin B, terbinafine, nystatin, griseofulvin, fluconazole, ketoconazole, biphenyl dimethyl dicarboxylate, silymarin ursodeoxycholic acid, sofalcone, omeprazole, pantoprazole, famotidine, itopride, mesalazine, cilostazol, clopidogrel, raloxifene, acyclovir, famciclovir, lamivudine, oseltamivir, clarithromycin, ciprofloxacin, cefuroxime, pranlukast, budesonide, fexofenadine, testosterone, prednisolone, estrogen, cortisone, hydrocortisone, dexamethasone, docetaxel, paclitaxel derivatives, doxorubicin, adriamycin, daunomycin, camptothecin, etoposide, teniposide and busulfan; and pharmaceutical derivatives and salts thereof.

13. A pharmaceutical or nutraceutical dosage form produced from the nanosuspension of claim 1 .

14. The nanosuspension of claim 8 wherein the sodium alginate has a viscosity of 75 mPa·s or less in a 1% solution in water at 20° C.

15. The nanosuspension of claim 8 wherein the sodium alginate has a viscosity of 50 mPa·s or less in a 1% solution in water at 20° C.

16. The nanosuspension of claim 1 wherein particles of the pharmaceutical active ingredient or nutraceutical active ingredient have a particle size distribution of from 10 to 1,000 nm for 10 to 90% of the particles determined based on a particle size normal distribution curve.

17. The nanosuspension of claim 1 wherein particles of the pharmaceutical active ingredient or nutraceutical active ingredient have a particle size distribution of from 10 to 400 nm for 10 to 90% of the particles determined based on a particle size normal distribution curve.